HEALTH PROGRAMS
One reusable intelligence layer. Focused disease programs.
NeuTigers starts with cardiometabolic risk, where SweetDeep™ has created the clinical and data foundation for new wearable-AI products, then extends that foundation through partner-led programs.
REUSABLE CLINICAL DATA ASSET
A longitudinal cardiometabolic knowledge base—not a collection of disconnected pilots.
Wearable, CGM, biomarker, glucose and participant-context data are linked across disease states to support reusable phenotypes, algorithms and evidence programs.
PRODUCT SYSTEM
One data asset has generated three cardiometabolic products.
The same governed data substrate supports distinct intended uses: non-invasive type 2 diabetes screening research, short-window glucose dynamics and prediabetes-focused development.
| Program | Indication / intended use | Data | Study status | Evidence | Partnership |
|---|---|---|---|---|---|
| SweetDeep™Cardiometabolic health | Wearable-enabled metabolic risk awareness and research workflows | Wearable physiology, glucose and contextual data | Clinical evidence available | Watch-CGM studies | Strategic partnering |
| MFDeep™Women’s health | Earlier fetal macrosomia risk stratification research | Maternal clinical data and fetal biometry | Active clinical development | French clinical collaboration | Co-development |
| Agentic DCT EngineClinical trials | Wearable-powered decentralized study operations and evidence generation | Wearable, study and participant data | Partner pilot | Platform workflow | Sponsored validation |
| Disease intelligence pipelineChronic & rare disease | New digital biomarkers for high-unmet-need conditions | Multimodal real-world health data | Exploratory | Research pipeline | Research collaboration |
Status labels describe the current research or collaboration stage. Capabilities described on this page are investigational and not FDA cleared; they do not imply regulatory clearance, approval, diagnostic use or commercial availability.
CARDIOMETABOLIC FLAGSHIP
Clinical evidence availableSweetDeep™
Two sensing modalities. One clinically grounded metabolic-intelligence platform. The initial consumer launch is a general wellness experience; screening claims are investigational and subject to regulatory authorization.
Discuss SweetDeep™ →
WOMEN'S HEALTH
Active clinical developmentMFDeep™
Wearable-AI and multimodal data research for earlier fetal macrosomia risk prediction in gestational diabetes.
Discuss MFDeep™ →
CLINICAL TRIALS
Partner pilotAgentic DCT Engine
A supervised, wearable-powered system for decentralized study operations, data quality and evidence generation.
Pilot the DCT engine →
Visual evidence is reproduced from the approved 2026 master deck for qualified review. Quantitative, clinical, collaborator and regulatory statements require final claims-register and permission approval before public launch.
PROGRAM DILIGENCE